Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design

Article Respiratory System

Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group

Olivier Hermine et al.

Summary: This study aimed to determine whether anti-interleukin (IL)-6 receptors improve outcomes in critically ill patients with COVID-19 pneumonia. The results showed that anti-IL-6 receptor treatment did not significantly increase the number of patients alive without the need for noninvasive ventilation (NIV) or mechanical ventilation (MV) by day 14.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Rheumatology

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

France X. Mariette et al.

Summary: Treatment with sarilumab did not improve early outcomes in patients with moderate-to-severe COVID-19 pneumonia. Further studies are warranted to evaluate the effect of sarilumab on long-term survival.

LANCET RHEUMATOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group

Olivier Hermine et al.

Summary: The combination of dexamethasone and tocilizumab did not improve the need for mechanical ventilation and mortality in patients with moderate-to-severe COVID-19 pneumonia. The safety of both treatments was similar.

ECLINICALMEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Olivier Hermine et al.

Summary: In this clinical trial of COVID-19 patients with pneumonia requiring oxygen support but not in the ICU, tocilizumab did not reduce WHO-CPS scores below 5 by day 4 but may have reduced the risk of needing noninvasive ventilation, mechanical ventilation, or death by day 14. There was no difference in mortality by day 28. Further studies are needed to confirm these preliminary results.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

Xavier Mariette et al.

Summary: The study aimed to determine the effectiveness of anakinra in improving outcomes of patients with mild-to-moderate COVID-19 pneumonia, but the results showed that anakinra did not show improvement in patient outcomes. Further studies are needed to assess the efficacy of anakinra in other selected groups of patients with more severe COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Review Pharmacology & Pharmacy